



# Biotech Daily

Wednesday October 5, 2011

*Daily news on ASX-listed biotechnology companies*

**\* ASX, BIOTECH UP: ANTISENSE UP 12.5%; SUNSHINE HEART DOWN 4%**

**\* RESMED AGM TO INCREASE INCENTIVE PLAN 55%, SAY-ON-PAY**

**\* ANTISENSE AGM ON PRIOR SHARE PLACEMENTS**

## MARKET REPORT

The Australian stock market recovered 1.4 percent on Wednesday October 5, 2011 with the S&P ASX 200 up 54.4 points to 3,926.5 points.

Ten of the Biotech Daily Top 40 stocks were up, eight fell, nine traded unchanged and 13 were untraded.

Antisense was the best, up 0.1 cents or 12.5 percent to 0.9 cents with 4.1 million shares traded.

Clinuvel climbed 9.1 percent; Impedimed was up 6.7 percent; Universal Biosensors rose five percent; QRX was up four percent; Mesoblast rose 2.75 percent; with Acrux, Biota, Cochlear, Resmed, Sirtex and Viralytics up one percent or more.

Sunshine Heart led the falls, down 0.2 cents or 4.3 percent to 4.5 cents, with 374,201 shares traded, followed by Starpharma down four percent to 96 cents with 838,338 shares traded.

Anteo, Bionomics, Genetic Technologies and Prima were down more than three percent; Nanosonics shed two percent; with CSL and Pharmaxis down by less than one percent.

## RESMED

Resmed's annual general meeting will vote to increase the incentive award plan by 54.7 percent to 35,475 shares, approve executive pay and advise on say-on-pay frequency. Known as say-on-pay, Section 951 of the 2010 US Dodd-Frank Wall Street reform and Consumer Protection Act requires companies to seek a non-binding advisory vote from stockholders on how frequently it should include a proposal regarding the approval of the compensation awarded to our executives.

Resmed said shareholders would vote on the approval on an advisory basis of compensation to named executives including executive chairman Dr Peter Farrell, former chief executive officer Kieran Gallahue, chief financial officer Brett Sandercock, general counsel David Pendarvis, chief operating officers Rob Douglas and Stein Jacobsen. The company said the meeting would vote on whether to have a say-on-pay every one, two or three years.

Resmed said the annual general meeting would also vote on the re-election of directors Dr Christopher Roberts and John Wareham.

The meeting will be held at Resmed, 1 Elizabeth Macarthur Drive, Bella Vista, Sydney, on November 16, 2011, at 10am (AEDT).

Resmed was up four cents or 1.4 percent to \$2.94 with 2.9 million shares traded.

## ANTISENSE

The Antisense annual general meeting will vote to approve two prior share placements and re-elect a director.

Antisense said shareholders would vote on the approval of the prior issue of 69,000,000 listed options, exercisable at 1.1 cents each by July 31, 2012 to Patersons Securities and 62,500,000 shares at 0.8 cents a share to Tempo Capital along with 31,250,000 unlisted options exercisable at 1.5 cents each by December 9, 2012.

Antisense said the annual general meeting would also vote on the re-election of director Dr Graham Mitchell.

The meeting will be held at Giorgio's Restaurant, 1235 High Street, Armadale, Victoria on November 8, 2011 at 3pm (AEDT).

Antisense was up 0.1 cents or 12.5 percent to 0.9 cents with 4.1 million shares traded.